18800-75-4

Usage

Uses

Used in Pharmaceutical Industry:
Pentanoic acid, 4,5-diamino-5-oxo-, phenylmethyl ester, monohydrochloride, (R)is used as an intermediate for the synthesis of Mifamurtide, a drug that is employed in the treatment of osteosarcoma. Mifamurtide increases the survival rate of nonmetastatic and metastatic patients undergoing chemotherapy for osteosarcoma, making it a crucial component in the development of this life-saving medication.
Chemical Properties:
Pentanoic acid, 4,5-diamino-5-oxo-, phenylmethyl ester, monohydrochloride, (R)is a white crystalline powder, which indicates its solid state and appearance. The specific chemical properties of Pentanoic acid, 4,5-diamino-5-oxo-, phenylmethyl ester, monohydrochloride, (R)-, such as solubility, reactivity, and stability, would depend on its molecular structure and the functional groups present in the molecule.

Upstream product

• 18800-73-2 benzyl N-tert-butyloxycarbonyl-L-γ-glutamate α-amide 
• 13574-13-5 Boc-Glu(OBzl)-OH 

Downstream Products

• 59524-67-3 Benzyl-t.-butyloxycarbonyl-L-Alanyl-D-isoglutaminat 
• 18814-49-8 tert-butoxycarbonyl-L-alanyl-D-isoglutamine benzyl ester 

Relevant academic research and scientific papers

Phosphotyrosine-containing dipeptides as high-affinity ligands for the p56(lck) SH2 domain

Src homology-2 (SH2) domains are noncatalytic motifs containing approximately 100 amino acid residues that are involved in intracellular signal transduction. The phosphotyrosine-containing tetrapeptide Ac-pYEEI binds to the SH2 domain of p56(lck) (Lck) with an affinity of 0.1 μM. Starting from Ac-pYEEI, we have designed potent antagonists of the Lck SH2 domain which are reduced in peptidic character and in which the three carboxyl groups have been eliminated. The two C-terminal amino acids (EI) have been replaced by benzylamine derivatives and the pY + 1 glutamic acid has been substituted with leucine. The best C-terminal fragment identified, (S)-1-(4-isopropylphenyl)ethylamine, binds to the Lck SH2 domain better than the C-terminal dipeptide EI. Molecular modeling suggests that the substituents at the 4-position of the phenyl ring occupy the pY + 3 lipophilic pocket in the SH2 domain originally occupied by the isoleucine side chain. This new series of phosphotyrosine-containing dipeptides binds to the Lck SH2 domain with potencies comparable to that of tetrapeptide 1.

Novel immunological adjuvant compounds and methods of preparation thereof

This application relates to novel immunological adjuvant compounds of the formula: STR1 wherein each of R and R1 are the same or different and are hydrogen or an acyl radical; R2 is an unsubstituted or substituted alkyl radical, or an unsubstituted or substituted aryl radical; R6 is an alkyl radical X is an aminoacyl moiety; and Y is D-isoasparagine or D-isoglutamine.